Arch Therapeutics (OTCMKTS:ARTH) received a $3.00 target price from equities researchers at HC Wainwright in a research report issued to clients and investors on Thursday. The brokerage currently has a “buy” rating on the biotechnology company’s stock.
A number of other research analysts also recently commented on ARTH. ValuEngine downgraded Arch Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, November 17th. Zacks Investment Research raised Arch Therapeutics from a “hold” rating to a “buy” rating and set a $0.75 price target for the company in a research note on Friday, December 1st. Finally, Ifs Securities upgraded Arch Therapeutics from an “outperform” rating to a “strong-buy” rating in a research report on Monday, February 5th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $2.17.
Arch Therapeutics (OTCMKTS:ARTH) opened at $0.32 on Thursday. The company has a market capitalization of $46.99, a PE ratio of -8.00 and a beta of 0.52. Arch Therapeutics has a 52 week low of $0.25 and a 52 week high of $0.89.
About Arch Therapeutics
Arch Therapeutics, Inc is a development-stage company. The Company operates as a biotechnology company. The Company focuses on developing products to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. The Company’s technology is based on a self-assembling peptide that creates a physical, mechanical barrier, which could be applied to seal organs or wounds that are leaking blood and other fluids.
Receive News & Ratings for Arch Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arch Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.